Abstract
Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients ( < 40%). Rejection although rare, remains a concern and the use of stimulating factors controversial. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether these patients should be treated with interferon-based therapies. Clinical trials of newer antivirals are urgently required in these patients who are at risk of rapid development of cirrhosis.
Keywords: Liver transplantation, hepatitis C, recurrenct viral hepatitis, HCV, liver disease, Immunosuppression, Calcineurin Inhibitors, Corticosteroids, viremia, Azathioprine, IL28B Polymorphisms
Anti-Infective Agents
Title: Recurrent Hepatitis C After Liver Transplantation
Volume: 10 Issue: 1
Author(s): Sandeep Mukherjee
Affiliation:
Keywords: Liver transplantation, hepatitis C, recurrenct viral hepatitis, HCV, liver disease, Immunosuppression, Calcineurin Inhibitors, Corticosteroids, viremia, Azathioprine, IL28B Polymorphisms
Abstract: Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients ( < 40%). Rejection although rare, remains a concern and the use of stimulating factors controversial. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether these patients should be treated with interferon-based therapies. Clinical trials of newer antivirals are urgently required in these patients who are at risk of rapid development of cirrhosis.
Export Options
About this article
Cite this article as:
Mukherjee Sandeep, Recurrent Hepatitis C After Liver Transplantation, Anti-Infective Agents 2012; 10 (1) . https://dx.doi.org/10.2174/2211362611201010034
DOI https://dx.doi.org/10.2174/2211362611201010034 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Plant-based Adjuvant in Vaccine Immunogenicity: A Review
Current Traditional Medicine Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly
Current Molecular Medicine Bridging Indigenous Knowledge and Scientific Evidence for Pharmacological Studies of <i>Phaleria macrocarpa</i>: A Systematic Review
The Natural Products Journal Evaluation of Micro-RNA Levels, Apoptosis and Oxidative Stress Markers in Patients Recieving Chemotherapy
Combinatorial Chemistry & High Throughput Screening Nanoparticle Interaction with Biomolecules: How it Shapes the Nano-Effects on Immunity
Current Bionanotechnology (Discontinued) The Complex Biology of FOXO
Current Drug Targets Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization
Anti-Cancer Agents in Medicinal Chemistry Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Influence of Mutations in the Hepatitis B Virus Genome on Virus Replication and Drug Resistance - Implications for Novel Antiviral Strategies
Current Medicinal Chemistry Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Immune Checkpoint Inhibitor Therapy and Risk of Myocarditis: A Review of the Literature
Current Immunology Reviews (Discontinued)